GARP Research Reiterates a 'Buy' on Luminex (LMNX); Molecular Diagnostics’ Top Line Contribution May Double Over Next 3 Years
Tweet Send to a Friend
GARP Research reiterates a 'Buy' rating on Luminex (Nasdaq: LMNX).
GARP analyst says, "We think Luminex’s bead-based xMAP, a technology ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
GARP analyst says, "We think Luminex’s bead-based xMAP, a technology ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
